Figure 1.
Therapy–triggered loss of plasma cell BCMA expression. Biopsy samples from 3 patients before initial anti-BCMA therapy (left, BCMA-naïve) are shown in contrast to biopsy samples after initial anti-BCMA therapy and prior to teclistamab treatment (right, Pre-Tec failure). (A) Patient 1 following belantamab mafoditin (bela) and cilta-cel treatment. (B) Patient 2 following cilta-cel treatment. (C) Patient 3 following belantamab treatment.

Therapy–triggered loss of plasma cell BCMA expression. Biopsy samples from 3 patients before initial anti-BCMA therapy (left, BCMA-naïve) are shown in contrast to biopsy samples after initial anti-BCMA therapy and prior to teclistamab treatment (right, Pre-Tec failure). (A) Patient 1 following belantamab mafoditin (bela) and cilta-cel treatment. (B) Patient 2 following cilta-cel treatment. (C) Patient 3 following belantamab treatment.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal